unbound from proteins in the incubation; HIM, human intestinal microsomes; HKM, human kidney microsomes; HLM, human liver microsomes; IC 50 , concentration of an inhibitor that causes a 50% decrease in enzyme activity; K i , inhibition constant that defines the affinity of a reversible inhibitor for an enzyme; K i,u , unbound inhibition constant; K m , Michaelis-Menten constant; K m,u , unbound Michaelis-Menten constant; LC/RAM/MS, liquid chromatography/radioactivity monitor/mass spectroscopy; LC-MS/MS, liquid chromatography-tandem mass spectrometry; MTT, methylthiazolyldiphenyltetrazolium bromide; nmDMD, nonsense mutation Duchenne muscular dystrophy; RAM, radioactivity monitor; UDPGA, uridine diphosphate glucuronic acid; UGT, uridine diphosphate glucuronosyltransferase; V max , maximum velocity.
oral dose of [ 14 C]-ataluren in mice, rats, dogs, and humans, ataluren was well absorbed and cleared primarily by metabolism. Biliary secretion was the major route for elimination of drug-related radioactivity in bile-duct cannulated rats. Ataluren acyl glucuronide was the only detectable metabolite in human plasma, and the major metabolic and clearance pathways in humans are similar to animal species. 20 The acceptable pharmacokinetic, toxicokinetic, and safety profiles of ataluren support the use of ataluren for chronic administration to patients with genetic disorders resulting from nonsense mutations.
Ataluren clinical development program consists of Phase 1 studies characterizing the absorption, metabolism, and excretion profile of ataluren and evaluating the pharmacokinetics and safety profiles in healthy subjects, [20] [21] [22] Phase 2 studies in patients with nonsense mutation genetic disorders, 5 and long-term Phase 2b/3 studies in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) and nonsense mutation cystic fibrosis (nmCF). [23] [24] [25] Ataluren has shown good tolerability in healthy subjects and patients, and has demonstrated clinical benefit in two multicenter, randomized, clinical trials to slow disease progression in patients with nmDMD. 24, 25 On this basis, ataluren received conditional marketing authorization for the treatment of nmDMD in ambulatory patients Extensive in vitro and in vivo studies have been conducted to characterize absorption, distribution, metabolism, excretion, pharmacokinetic/toxicokinetic properties, and drug interaction potentials of ataluren. Most recent publications include ataluren pharmacokinetics in Japanese healthy subjects, 22 and the absorption, metabolism, and excretion following a single oral dose of [ 14 C]-ataluren in mice, rats, dogs, and humans. 20 The additional manuscripts in preparation include in vitro and in vivo stability assessment of ataluren acyl glucuronide, evaluation of drug metabolizing enzyme-and transporter-mediated drug-drug interaction potentials in healthy subjects, pharmacokinetics evaluation of ataluren in special population, and safety, pharmacokinetic, and pharmacodynamic assessments in nmDMD patients aged ≥ 2 to < 5 years, etc. The purpose of the current manuscript is to describe the in vitro metabolism and enzyme kinetics of ataluren and its interaction with CYP enzymes.
The results presented here have provided the understanding of ataluren disposition and metabolism in vitro and informed the need and design of additional clinical studies to investigate the potential drugdrug interactions in human. After centrifugation, the entire ultrafiltrate was weighed and analyzed for radioactivity using liquid scintillation counting. The percent bound = (1-C u /C m )×100, where C u is the concentration of radioactivity in the ultrafiltrate and C m is the concentration of radioactivity in the plasma before centrifugation. 
| MATERIAL S AND ME THODS

| Materials
| ME THODS
| In vitro metabolism and plasma protein binding
| In vitro metabolism
| Plasma protein binding
| Reaction phenotyping and kinetics for the formation of ataluren acyl glucuronide
| Recombinant human UGT enzymes
| Correlation analysis
Ataluren at a concentration of 10 μmol/L, was incubated (n = 2) with 16 individual HLM at 0.5 mg protein concentration/mL for 0 and 60 minutes at 37°C. Enzyme activities for UGTs 1A1, 1A4, 1A6, 1A9, and 2B7 were precharacterized under optimized conditions by TA B L E 1 Analysis of the correlation between the rate of disappearance of ataluren, the rate of the glucuronide formation, and marker UGT enzyme activity in a bank (n = 16) of individual human liver microsomes for hepatic, renal, and intestinal data, respectively. 26
| Incubations of ataluren with microsomes from extrahepatic tissues
| Enzyme kinetics for the formation of ataluren acyl glucuronide
| Correction for BSA binding
The high-throughput membrane ultrafiltration method 27 was used to determine the fraction unbound in the incubation (n = 3).
Incubation mixtures and procedures were essentially the same as 
| CYP inhibition and induction
| CYP inhibition
The metabolic reactions that were monitored and probe substrate concentrations used are shown in Table S1 . (Table S1 ).
Incubations were stopped with the addition of ice-cold acetonitrile.
Metabolite formation in incubations with test compound and control inhibitors was assessed with LC-MS/MS methods for each of the reaction products as described in Table S2 . For inhibition constant with validated LC-MS/MS methods for each of the reaction products as described in Table S2 . Enzymatic activity for each CYP was calculated using the absolute amount of metabolite formed (pmol) divided by hepatocytes in the incubation (million cells) and the incubation time (minute). The relative fold induction in enzymatic activity was calculated by comparing the rate of metabolite formation for treatment groups to that of the solvent control group (reported as vehicle control%) or positive control group (reported as positive control%). 
| CYP induction
| LC-MS/MS analysis
| Metabolism of Ataluren in HLM
| Reaction phenotyping for the formation of ataluren acyl glucuronide
Quantification of ataluren loss and ataluren-O-1β-acyl glucuronide formation was carried out with an LC-MS/MS system, which con- (internal standard), respectively. 
| Kinetics for the formation of ataluren acyl glucuronide
| Data analysis
The study design was not powered for statistical analysis. All assays were run in singlet, duplicate or triplicate and were used only to test 
| Plasma protein binding
The percentage protein binding of [ 14 C]-ataluren (mean ± standard deviation, n = 3) was 98.4 ± 0.5, 98.7 ± 0.2, 97.5 ± 0.2, 99.7 ± 0.1, and 99.6 ± 0.1 in mouse, rat, dog, monkey, and human plasma, respectively. No marked concentration-dependent binding over the target concentration range of 50 to 50 000 ng/mL (0.175 to 175 µmol/L) in plasma from all species investigated was observed.
| Reaction phenotyping for ataluren glucuronidation
The greatest loss of ataluren and the greatest formation of ataluren-O-1β-acyl glucuronide was seen with recombinant human UGT1A9 (32.7% ataluren loss and 187 pmol/mg/min ataluren glucuronide formation after 60 minutes incubation, n = 2) followed by UGT1A7 significantly correlated with one another (r = 0.948) confirming that the same enzyme (UGT1A9) was responsible for both the loss of ataluren and ataluren acyl glucuronide formation (Table 1 and Figure 2 ).
The loss of ataluren and the formation of ataluren-O-1β-acyl glucuronide did not correlate significantly with any of the other enzyme activities evaluated (ie, UGTs 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A10, 2B4, 2B7, 2B15, and 2B17). Since UGT1A7 is not expressed in human liver, glucuronide formation and substrate loss could not be correlated with UGT1A7 activity ( Table 1 ).
Glucuronidation of ataluren was observed in kidney and intestine as well as in liver microsomes, but not in lung microsomes. After 60 minutes incubation, ataluren loss was 31.4%, 94.3%, and 34.4% (n = 1), and ataluren glucuronide formation rate was 62.0, 48.4, and 29.0 pmol/mg/ min (n = 1) in liver, kidney, and intestinal microsomes, respectively.
| Ataluren glucuronidation kinetics
The results are shown in Table 2 , Figure 3 and 
| CYP inhibition potential
The appropriate positive controls used in this study inhibited the enzyme activities at acceptable levels indicating that the test system was functional (data not shown). As summarized in Table S3 , at concentrations up to 400 μmol/L (n = 3), ataluren did not inhibit enzyme activity for CYPs 1A2, 2B6, 2C19, 2D6, and 3A4/5. The IC 50 values were estimated to be greater than 400 μmol/L, and due to solubility limitations, K i values were not determined for these enzymes.
Ataluren inhibited CYP2C8 and CYP2C9 activities with IC 50 values of 165 µmol/L and 134 µmol/L, respectively. The mechanism study indicated that ataluren is a noncompetitive inhibitor of CYP2C8 with K i (mean ± SE, n = 3) of 169 ± 6.19 µmol/L and is a competitive inhibitor of CYP2C9 with K i (mean ± SE, n = 3) of 75.4 ± 4.42 µmol/L ( Figure 5 ).
| CYP induction potential
Hepatocytes from all three human donors used in the study responded well to exposure of all prototypical inducers. At the concentrations tested, ataluren was not cytotoxic as indicated by methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay (data not shown). Ataluren did not induce the activities of CYPs 1A2, 2A6, 2C8, 2C19, 2E1, or 3A4 relative to the vehicle control, 1% DMSO, but showed approximately 1.7-and 1.5-fold induction (n = 3) over vehicle control at 400 µmol/L for CYP2B6 and CYP2C9 activity, respectively. The mean enzyme activities are summarized in Table S4 .
| D ISCUSS I ON AND CON CLUS I ON
The findings of the current studies show that the direct conjugation of ataluren with glucuronic acid to form ataluren acyl glucuronide is the primary metabolic pathway of ataluren, consistent with in vivo observations.20 CYP plays only a minimal role in the metabolism of ataluren. UGT1A9 was the major enzyme responsible for the formation of ataluren-O-1β-acyl glucuronide. UGT1A7 was found to be the minor enzyme for producing ataluren acyl glucuronide. Ataluren UGT reaction phenotyping results are similar to propofol glucuronidation in microsomes from human liver, intestine, and kidney. 26 They are also consistent with the fact that UGT1A9 is mainly expressed in liver and kidney and is more abundant in kidney than in liver, is expressed at low levels in the small intestine and is not expressed in the lung. 28, 29 UGT1A7 is minimally expressed in the liver and at low levels in the kidney, small intestine, and similar to UGT1A9, it is not expressed in the lung. 28, 29 In vitro kinetic data revealed that human kidney microsomes is about 3.7-fold more active than human liver microsomes in ataluren glucuronidation, in terms of CL int,u /mg protein, indicating that in addition to the liver, the kidney is also a key organ for the metabolism and disposition of ataluren in human. Though HIM showed relatively low CL int,u for ataluren glucuronidation activity, contribution of intestinal UGTs cannot be excluded for ataluren first pass metabolism in small intestine following oral dose. UGT2B7. 31 In contrast, BSA increased V max in addition to lowering the K m for UGT1A9 31 and showed a minimal effect on UGT1A1 and UGT1A6. 32 For two (buprenorphine and carvedilol) of the 10 compounds in HLM, 2% BSA reduced CL int,u . 33 However, the results of the effect of BSA have been inconsistent. One study found that 2% BSA decreased apparent V max for propofol-O-glucuronidation (UGT1A9), whereas increased V max for zidovudine glucuronidation (UGT2B7) in HLM and in recombinant human UGTs. 34 In this study, different concentrations of BSA (0%, 0.5%, 1%, and 2%) were used to evaluate the effect of BSA on ataluren glucuronidation using recombinant human UGT1A9 and human liver, kidney, and intestinal microsomes. Similar to results using propofol and 4-methylumbelliferone as substrates, 32 BSA increased total apparent K m and protein binding in a BSA concentration-dependent manner, and had minimal effect on V max . BSA increased CL int,u due to the decrease in K m,u in all tested systems at all BSA concentration tested.
However, the maximal effect on CL int,u were system/tissue dependent and were increased approximately 1.6-, 10-, 4.8-, and 3.7-fold for recombinant UGT1A9, and human liver, kidney, and intestine microsomes, respectively. Regarding the use of BSA, 2% BSA is most frequently used in different test systems. However, based on limited data, the BSA concentration may also play a role in enzyme activation in a substrate/system-dependent manner. 32, 35, 36 For ataluren, a benzoic acid derivative, 1% BSA was the optimal concentration, which is in agreement with Gill et al that 1% BSA was optimal for acids and 2% was the best for base/neutral. 26 These results indicate that BSA titrations may be necessary for compounds with low depletion and high protein binding.
Ataluren did not inhibit enzyme activity for CYPs 1A2, 2B6, in DMD patients, the mean C max of ataluren at the steady state is around 79.9 μmol/L. Since the protein binding of ataluren in human plasma is high (99.6%), the free C max of ataluren at the steady state is around 0.32 µmol/L (using free fraction value of 0.4% as measured) or 0.80 µmol/L (to be conservative assuming free fraction value of 1%), and thus is much lower than K i,u values, 169 µmol/L for CYP2C8 and 75.4 µmol/L for CYP2C9. These data indicate that ataluren will likely not exhibit any clinically relevant effect due to CYP inhibition.
At concentrations up to 400 µmol/L in cultured primary human hepatocytes, ataluren did not induce the activities of CYPs 1A2, 2A6, 2C8, 2C19, 2E1 and 3A4, except for a mild 1.7-and 1.5-fold induction over vehicle control at 400 µmol/L for CYP2B6 and CYP2C9 activity, respectively. This induction is considered not significant or clinically relevant, and thus, ataluren interaction with other concomitantly administered drugs due to enzyme induction is less likely.
In summary, results of in vitro metabolism studies showed that CYP-mediated metabolism of ataluren is minimal, whereas acyl glucuronidation is the major metabolic pathway. UGT1A9 is the major enzyme that catalyzes glucuronidation of ataluren in liver and kidney. Enzyme kinetic studies indicated that in addition to the liver, the kidney is also a key organ for the metabolism and disposition of ataluren in humans, whereas other UGTs may be also involved in this reaction in the intestine. Ataluren showed no or little potential to inhibit or induce most of the CYP enzymes.
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